Entrectinib (** Rozlytrek **)

Targeted Therapy

EU Not submitted to EMA ES Not available 2 Clinical Trials

Description

Entrectinib is used in the treatment of NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer (NSCLC); it has shown efficacy in patients with advanced or metastatic cancers; however, its use in colorectal cancer (CRC) remains investigational as of now.

Mechanism of Action

Entrectinib is a selective, potent inhibitor of tropomyosin receptor kinase (TRK) A/B/C and ROS1 kinases; it binds to the ATP-binding site of these kinases, thereby inhibiting their activity and downstream signaling pathways.

Side Effects

Hemorrhage; fatigue; constipation; dysgeusia; dizziness; anemia; nausea; vomiting; increased AST levels; increased ALT levels

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05525858 Not Applicable
Recruiting
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
South Korea
NCT02568267 Phase 2
Active, not recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
United States, Australia, Belgium, China, France, Germany, Hong Kong, Italy, Jap

Quick Info

Brand Name** Rozlytrek **
CategoryTargeted Therapy
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Regorafenib
Targeted Therapy
107 trials
Rego
Targeted Therapy
107 trials
Fruquintinib
Targeted Therapy
57 trials
Encorafenib
Targeted Therapy
26 trials
Binimetinib
Targeted Therapy
22 trials
Trametinib
Targeted Therapy
22 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.